Celgene Corp logo

Celgene Corp

CELG · NASDAQ · HealthTechnology, Biotechnology · Founded 1986

Celgene Corporation is an American pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS) since its acquisition in 2019.

Current Price
—
Market Cap
—
Return Since Last Split
—
Last Split
Jun 26, 2014
Total Splits
1
Cumulative Multiple
2×

What If You Bought CELG Earlier?

Investment
Purchase Date (Before Split)
Worth Today
—
200 shares · 2×

Estimate based on split history only. Excludes dividends, fees, taxes, and intraday movement.

Stock Split History

Newest split first. Cumulative multiple = compounded growth from that date to today.

Split DatePrice BeforeRatioSplit MultipleCumulative
Jun 26, 2014—2-for-12×2×

Celgene Corp Market Cap Timeline

A validated annual market-cap history is unavailable from the current sources. The current market-cap snapshot, when shown above, is not treated as historical evidence. Split markers cover all 1 recorded split. Filled dots have market-cap data for that year; hollow dots mark split years outside market-cap source coverage.

Validated annual history unavailable

At least two source-validated annual observations are required before this page draws a market-cap timeline. A current snapshot is not treated as historical trend data.

Recorded split dates

Frequently Asked Questions

Celgene Corp's latest record in the split calendar is a 2-for-1 forward split effective 2014-06-26.
Stay in the loop

Never Miss a Stock Split Again

Get personalized stock split alerts. Choose what you receive and how often.

Your email is securely stored. We’ll only contact you about updates you choose. Unsubscribe anytime.